small molecule

TWYNEO

BENZOYL PEROXIDE; TRETINOIN

Loss of exclusivityMay 2041latest FDA-listed patent expiry
CompanyMayne Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameTWYNEO
Active ingredientBENZOYL PEROXIDE; TRETINOIN
Strength3%;0.1%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 2021
Marketing statusRX

Listed patents

PatentExpiresType
12491163May 2041product
12133919May 2041product
12257348May 2041product
12295935December 2040use U-3987
12357602July 2038product
10420743July 2038use U-3194
12053546June 2032product
10653899December 2030product
12070629December 2030product
11071878December 2030product
9868103August 2028product
8617580February 2028product
12156946February 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.